Yui Jennifer C, Preskill Carina, Greenlund Laura S
Department of Medicine, Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN.
Department of Medicine, Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2017 Aug;92(8):1223-1226. doi: 10.1016/j.mayocp.2017.04.007.
Anticoagulation is common in patients undergoing arthrocentesis and joint injections. Previous studies have established the safety of continuing anticoagulation with warfarin before joint aspirations/injections with only a small increased risk of bleeding, but no data are available regarding the use of direct oral anticoagulants (DOACs) and joint aspirations/injections. The objective of this study was to determine the rate of bleeding complications associated with arthrocentesis and joint injection in patients receiving DOACs. We performed a retrospective review of adult patients at Mayo Clinic in Rochester, Minnesota, who were being treated with DOACs and underwent outpatient joint aspiration and/or injection between October 1, 2010, and October 31, 2016. In 1050 consecutive procedures, there were no bleeding complications. Arthrocentesis and joint injections in patients receiving DOAC therapy are safe procedures, and there is no need to withhold anticoagulation treatment before the procedure.
抗凝治疗在接受关节穿刺和关节注射的患者中很常见。以往的研究已证实,在关节穿刺/注射前继续使用华法林抗凝是安全的,仅出血风险略有增加,但关于直接口服抗凝剂(DOACs)与关节穿刺/注射的使用尚无数据。本研究的目的是确定接受DOACs治疗的患者关节穿刺和关节注射相关的出血并发症发生率。我们对明尼苏达州罗切斯特市梅奥诊所接受DOACs治疗且在2010年10月1日至2016年10月31日期间接受门诊关节穿刺和/或注射的成年患者进行了回顾性研究。在连续1050例操作中,未出现出血并发症。接受DOAC治疗的患者进行关节穿刺和关节注射是安全的操作,无需在操作前停用抗凝治疗。